Saturday, September 23, 2017 5:26:30 PM
September 23rd, 2017 - Filed Under - by Stacy Sanders
Cantor Fitzgerald reaffirmed their buy rating on shares of Versartis, Inc. (NASDAQ:VSAR) in a report issued on Friday. They currently have a $14.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $34.00.
https://www.dailypolitical.com/2017/09/23/versartis-inc-vsar-given-buy-rating-at-cantor-fitzgerald.html
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM